Przejdź do menu Przejdź do treści

Wybrane publikacje

  • Grzymajlo K, El Hafny-Rahbi B, Kieda C. Tumour suppressor PTEN activity is differentially inducible by myo-inositol phosphates. J Cell Mol Med. 2023 Feb 27. doi: 10.1111/jcmm.17699.
  • Oknińska M, Mackiewicz U, Zajda K, Kieda C, Mączewski M. New potential treatment for cardiovascular disease through modulation of hemoglobin oxygen binding curve: Myo-inositol trispyrophosphate (ITPP), from cancer to cardiovascular disease. Biomed Pharmacother. 2022 Oct;154:113544. doi: 10.1016/j.biopha.2022.113544.
  • Thinard R, Farkas AE, Halasa M, Chevalier M, Brodaczewska K, Majewska A, Zdanowski R, Paprocka M, Rossowska J, Duc LT, Greferath R, Krizbai I, Van Leuven F, Kieda C, Nicolau C. „Endothelial Antibody Factory” at the Blood Brain Barrier: Novel Approach to Therapy of Neurodegenerative Diseases. Pharmaceutics. 2022 Jul 6;14(7):1418. doi: 10.3390/pharmaceutics14071418.
  • Maksym RB, Hoffmann-Młodzianowska M, Skibińska M, Rabijewski M, Mackiewicz A, Kieda C. Immunology and Immunotherapy of Endometriosis. J Clin Med. 2021 Dec 15;10(24):5879. doi: 10.3390/jcm10245879.
  • El Hafny-Rahbi B, Brodaczewska K, Collet G, Majewska A, Klimkiewicz K, Delalande A, Grillon C, Kieda C. Tumour angiogenesis normalized by myo-inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response. J Cell Mol Med. 2021 Apr;25(7):3284-3299. doi: 10.1111/jcmm.16399.
  • Oknińska M, Zambrowska Z, Zajda K, Paterek A, Brodaczewska K, Mackiewicz U, Szczylik C, Torbicki A, Kieda C, Mączewski M. Right ventricular myocardial oxygen tension is reduced in monocrotaline-induced pulmonary hypertension in the rat and restored by myo-inositol trispyrophosphate. Sci Rep. 2021 Sep 9;11(1):18002. doi: 10.1038/s41598-021-97470-6.
  • Oknińska M, El-Hafny-Rahbi B, Paterek A, Mackiewicz U, Crola-Da Silva C, Brodaczewska K, Mączewski M, Kieda C. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells. J Cell Mol Med. 2020 Feb;24(3):2272-2283. doi: 10.1111/jcmm.14909.
  • Klimkiewicz K, Weglarczyk K, Collet G, Paprocka M, Guichard A, Sarna M, Jozkowicz A, Dulak J, Sarna T, Grillon C, Kieda C. A 3D model of tumour angiogenic microenvironment to monitor hypoxia effects on cell interactions and cancer stem cell selection. Cancer Lett. 2017 Jun 28;396:10-20. doi: 10.1016/j.canlet.2017.03.006.
  • Collet G, Szade K, Nowak W, Klimkiewicz K, El Hafny-Rahbi B, Szczepanek K, Sugiyama D, Weglarczyk K, Foucault-Collet A, Guichard A, Mazan A, Nadim M, Fasani F, Lamerant-Fayel N, Grillon C, Petoud S, Beloeil JC, Jozkowicz A, Dulak J, Kieda C. Endothelial precursor cell-based therapy to target the pathologic angiogenesis and compensate tumor hypoxia. Cancer Lett. 2016 Jan 28;370(2):345-57. doi: 10.1016/j.canlet.2015.11.008.
  • Kieda C, El Hafny-Rahbi B, Collet G, Lamerant-Fayel N, Grillon C, Guichard A, Dulak J, Jozkowicz A, Kotlinowski J, Fylaktakidou KC, Vidal A, Auzeloux P, Miot-Noirault E, Beloeil JC, Lehn JM, Nicolau C. Stable tumor vessel normalization with pO₂ increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment. J Mol Med (Berl). 2013 Jul;91(7):883-99. doi: 10.1007/s00109-013-0992-6.